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face-to-face cognitive behaviour therapy versus
treatment as usual in managing fear of cancer
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Abstract
Background: Fear of cancer recurrence (FCR) is one of the most frequently cited problems by cancer survivors.
More than one third report high FCR, which is a clinical concern due to its association with negative health
outcomes. The aim of the current study is to evaluate the efficacy of cognitive behaviour therapy (CBT) in reducing
FCR in high fearful cancer survivors.
Methods/design: The SWORD-study has a randomised controlled design with two arms. A sample of 104 high fearful
cancer survivors (breast, prostate or colorectal cancer) will be recruited from local hospitals. Cancer survivors will be
randomised to receive CBT (intervention condition) or treatment as usual (control condition). For those in the
intervention condition, the therapy will be individually delivered in a combination of 5 face-to-face therapy sessions
and 3 online or telephone sessions by a trained therapist. Furthermore, these survivors will have access to a supportive
website (or workbook) throughout the therapy. Survivors in the control condition will not receive the intervention and
will not have access to the website. The primary outcome will be severity of fear of recurrence (Cancer Worry Scale).
Quality of life (EORTC Quality of Life Questionnaire Core 30) and general psychological wellbeing will be assessed as
secondary outcomes. Assessments will take place at baseline (before random assignment), at 3, 9 and 15 months after
the baseline assessment. The study has been approved by an ethical review board.
Discussion: If the intervention proves to be effective an evidence-based therapy to manage high FCR will become
available for use in clinical practice.
Keywords: Fear of cancer recurrence, Cancer survivors, Intervention, Cognitive behaviour therapy, Randomised
controlled trial, Oncology
Background
The number of people diagnosed with cancer is steadily
increasing while medical advancements have signifi-
cantly decreased cancer mortality rates. In the period be-
yond diagnosis and active treatment cancer survivors are
faced with several emotional challenges. Handling fear of
cancer recurrence (FCR) is one of the most prominent
ones (Crist & Grunfeld 2012).
FCR is defined as ‘the fear or worry that the disease
will return or progress in the same organ or in another
part of the body’ (Vickberg 2003). FCR is a universal
concern that manifests itself on a continuum, with mild
uncertainty and worry on one end to severe FCR on the
other end. A certain level of FCR is therefore considered
normal and may even be functional; it motivates appro-
priate self-protective responses (e.g. staying alert for signs
of a potential recurrence). However, high FCR can detri-
mentally affect a survivors’ emotional wellbeing (Simard
et al. 2013) and may persist for years after completion of
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medical treatment (Savard & Ivers 2013; Deimling et al.
2006).
Moderate to high FCR is present in about 30 to 70%
of cancer survivors (Savard & Ivers 2013; Custers et al.
2014; Thewes et al. 2012; Simard & Savard 2007). High
FCR represents a form of distress related to the illness
and aspects of treatment e.g. the cancer itself, follow-up
care or periodic examinations. It is also related to psy-
chosocial concerns such as worries about the future, dis-
ability or death (Mehnert et al. 2009). FCR is in the top
five of greatest concerns for cancer survivors and has
consistently been identified as one of the most cited un-
met needs (Simard et al. 2013; Armes et al. 2009). Even
though the problem is frequently encountered in clinical
practice, no clear consensus exists on the best manage-
ment strategies due to the scarcity of evidence-based
therapies. This makes FCR a challenging problem for
many survivors and health care providers (Thewes et al.
2014).
Interventions for FCR
A more detailed description of intervention studies that
have specifically addressed FCR (or related constructs)
can be found in Additional file 1: Appendix A. Only one
trial specified FCR as primary outcome of interest. Lebel
et al., (2014) published a feasibility and preliminary out-
come study of a single-arm 6-week cognitive existential
group intervention to address moderate to high FCR in
breast- and gynaecological cancer survivors. A decrease
in FCR was found immediately following completion of
the therapy and this effect was sustained at the 3-month
follow-up. In 71% of the cancer survivors FCR could be
classified as reliably improved and none of the cancer
survivors showed deterioration (Lebel et al. 2014).
A construct that shares some defining features with
FCR is fear of progression (FoP), the fear that the disease
will further spread or progress in the body. A trial by
Herschbach et al. (Herschbach et al. 2010) compared the
effect of two four-session group interventions (cognitive
behaviour therapy vs. supportive-experiential group ther-
apy) and usual care on reducing dysfunctional FoP
(Herschbach et al. 2010). Both interventions were car-
ried out during cancer rehabilitation. FoP decreased sig-
nificantly over time (up to 12-month follow-up) in both
intervention groups in contrast to the control group.
Those with metastatic disease or a recurrence (21%)
benefitted most from the interventions (Lebel et al.
2014). A secondary analysis of this data by Sabariego
et al., (2011) showed superior cost-effectiveness of group
CBT over supportive-experiential group therapy for pa-
tients with high FoP (Sabariego et al. 2011).
Four intervention studies to improve generic emotional
outcomes in breast cancer survivors addressed FCR as
secondary measure (see Additional file 1: Appendix B).
Two studies by Lengacher et al. 2009, 2011 investigated
short-term effects of group mindfulness-based stress re-
duction (MBSR) on psychological status in breast cancer
survivors. In the first study, a randomised controlled trial
(RCT), breast cancer survivors participating in a 6-week
MBSR programme reported a significant reduction in
FCR over time compared to breast cancer survivors on a
waitlist control group Lengacher et al. 2009 A second
study by Lengacher et al., (2011) found significant im-
provement in FCR after completion of an 8-week
MBSR programme (Lengacher et al. 2011). Both studies
have only assessed short-term effects of the intervention
and no information on long-term efficacy is available
(Lengacher et al. 2009; Lengacher et al. 2011). The third
study, a non-randomised trial, reported a significant de-
cline in levels of FCR (cancer worry) following a 12-week
emotion regulation group intervention targeted at anxiety
and distress in breast cancer survivors. Yet, no long-term
beneficial effects were found at 6-month or 12-month
follow-up (Cameron et al. 2007). Finally, a brief self-
guided nurse delivered uncertainty management inter-
vention found no significant differences between the
intervention and control group (Mishel et al. 2005). We
are aware of two separate intervention trials for FCR cur-
rently in progress: Conquer Fear (Butow et al. 2013) and
the AFTER-intervention (Humphris & Ozakinci 2008).
Results of these studies have not yet been published.
To summarize, published intervention studies provide
promising results in terms of beneficial effects of psy-
chological interventions for FCR and related constructs.
However, these studies had some limitations. While lit-
erature shows that moderate to high FCR is a universal
problem in cancer survivors interventions have almost
solely focused on survivors with breast- or gynaeco-
logical cancer (Herschbach et al. 2010; Lengacher et al.
2009; Lengacher et al. 2011; Mishel et al. 2005). Further-
more, information on treatment efficacy for long-term
cancer survivors is limited because FCR was mainly ad-
dressed during the first year after diagnosis (Herschbach
et al. 2010; Lengacher et al. 2009; Lengacher et al. 2011).
Therefore, it is hard to generalise findings of efficacy
and feasibility beyond women’s cancers to other cancer
types, to men and to long-term cancer survivors. Only
two studies mention screening for high FCR as part of
their standard eligibility procedure (Lebel et al. 2014;
Herschbach et al. 2010). By screening for high (dysfunc-
tional) FCR, it is possible to identify those with the high-
est care need and to select those who might benefit
most from the intervention. The SWORD-study was de-
veloped to address above mentioned limitations.
Current study
This paper describes the development of the interven-
tion and study protocol for the SWORD-study (SWORD
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is the acronym for Survivors’ Worries of Recurrent Dis-
ease). In this study an intervention known as “Beyond
Fear” will be evaluated with regard to its efficacy in man-
aging high FCR among breast, colorectal and prostate
cancer survivors. In an RCT both the short-term and
long-term effects of individual CBT for FCR will be
investigated.
Our intervention expands on the theoretical formula-
tion of FCR as a multidimensional construct proposed
by Lee-Jones (1997; Lee-Jones et al. 1997). We updated
this original formulation with recent research findings
and clinical experience. According to our framework as
shown in Figure 1, FCR is a distressing emotion main-
tained by dysfunctional cognitive thinking patterns such
as recurring unhelpful thoughts, negative (illness) beliefs,
intrusive images or persistent rumination. These think-
ing patterns cause a person to interpret certain events or
internal stimuli as potentially threatening or harmful to
one’s physical health and wellbeing, thereby triggering
FCR. Consequently, behavioural strategies that are
intended to reduce the fear, such as avoidance, excessive
self-monitoring or safety-seeking behaviours, maintain
FCR by preventing change in cognitive appraisal and/or
by providing further exposure to triggers of FCR. While
these behaviours may provide short-term alleviation of
fear, they may actually maintain the fear on the long run
(Lee-Jones et al. 1997; Leventhal et al. 1980). CBT
targets high FCR by changing dysfunctional thinking
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Figure 1 Theoretical model fear of cancer recurrence.
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patterns and maladaptive behaviours as specified in this
model.
Aims
The primary aim of the SWORD-study is to evaluate the
efficacy of a combination of online and face-to face cog-
nitive behaviour therapy (blended CBT) in reducing the
impact of FCR in breast, colorectal and prostate cancer
survivors. The aim is not to remove all FCR, but rather
to reduce its severity in order to improve quality of life.
Methods/design
The SWORD-study design and intervention are described
conform the CONSORT guidelines for evaluation of ran-
domised controlled trials (Schulz et al. 2010) and conform
the CONSORT extension for non-pharmacological treat-
ment interventions (Boutron et al. 2008).
Trial design
The SWORD-study is a longitudinal, multicentre, two-
arm, randomised controlled trial with one intervention
condition (CBT) and one control condition; treatment
as usual (TAU). Four assessments will take place for
both trial conditions: baseline (T0, before randomisa-
tion), 3 (T1), 9 (T2) and 15 months (T3) after the base-
line assessment. For survivors in the intervention
condition, the CBT will take place between the first and
second assessment. The longitudinal design allows for
the assessment of both short-term and long-term effects
of the intervention.
Ethical consideration
The SWORD-study has been approved by the ethical re-
view board of the Radboud University Medical Center
(CMO Arnhem-Nijmegen). Approval of local ethics has
been obtained in centres where recruitment will take
place. Only survivors who have completed written in-
formed consent will be allowed to participate. The study
will be conducted in compliance with the guidelines for
Good Clinical Practice and the Declaration of Helsinki
(Pieterse 2010; World Medical Association & Declaration
of Helsinki 2013). This trial is registered in the Netherlands
National Trial Register (trial number NTR4423).
Participants and procedure
A total of 104 (breast, prostate or colorectal) cancer sur-
vivors with high FCR are to be enrolled in this study.
They will be randomly allocated to receive either CBT
(n = 52, intervention condition) or TAU (n = 52, control
condition). Cancer survivors will be recruited from out-
patient clinics at an academic centre and several general
hospitals in the Netherlands. Recruitment will take place
at all sites simultaneously until the desired sample size is
reached. Nurse practitioners are asked to provide an
envelope containing study information (and an entry
form) to all cancer survivors who are eligible for study
participation based on information from their medical rec-
ord. If interested to participate, a person will complete the
entry form at home and send it to the researcher (MW)
who will then contact them by phone to provide further
study information and to address questions. Those willing
to participate are asked to provide written informed con-
sent and to fill-out a screening questionnaire. After receipt
of the completed questionnaire, the researcher will con-
tact the patient once more to discuss the screening out-
come and to second check all eligibility criteria.
Eligibility
Cancer survivors will be eligible to participate if they: (1)
have completed primary treatment (with curative intent)
for breast, colorectal or prostate cancer at least 6 months
and not more than 5 years ago; (2) are disease-free at
the moment of study inclusion, as defined by the ab-
sence of somatic disease activity parameters; (3) are at
least 18 years of age; (4) score ≥ 14 on the Cancer Worry
Scale, indicating high FCR; (5) have sufficient Dutch lan-
guage skills to fill out questionnaires, to understand
written text and to engage in active conversation; (6) are
able to travel to the Radboud University Medical Center
(RUMC) for CBT; (7) have given written informed con-
sent. Cancer survivors are not eligible to participate if
they 1) already receive psychological/psychiatric treat-
ment at moment of inclusion; or 2) have a second pri-
mary tumour at moment of inclusion.
Sample size
The sample size is calculated for the primary outcome
FCR as measured with the Cancer Worry Scale (Custers
et al. 2014). To detect a medium difference in FCR
(Cohen’s d = 0.50), with a two-sided type I error rate of
0.05 and a power of .80, a sample size of 128 patients is
needed. To correct for the baseline measurement as co-
variate the sample size is multiplied with the factor (1-
r2), where r denotes the correlation between the baseline
and post-intervention FCR (0.6 based on preliminary re-
search) (Heinrichs et al. 2012). Therefore, a total sample
size of 82 patients is desired. Because of an anticipated
attrition rate of 20%, 52 patients are required per condi-
tion (104 total) (Lebel et al. 2014).
Randomisation
After completion of baseline assessment survivors will
be allocated to CBT or TAU according to a computer
generated randomisation list, with a 1:1 allocation ratio
using a fixed block size of six participants. Stratification
by cancer type (breast, colorectal and prostate cancer)
will be applied Randomisation is computerised, using a
randomisation website specifically designed for this study.
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An independent secretary will enter all necessary patient
data into the programme and will communicate the ran-
domisation outcome (CBT or TAU) to the researcher who
further informs the study participant. Cancer survivors al-
located to the CBT condition will be assigned to one of
two therapists according to therapist availability.
Intervention
Developmental process
The development of the intervention consisted of five
stages:
● Needs assessment: Breast cancer survivors (n = 130)
were approached with a ‘need for help’ question and the
Cancer Worry Scale (CWS) (Custers et al. 2014). All
survivors were asked if they would accept CBT specific-
ally focused on managing FCR when experiencing high
FCR (response options: yes/possibly/no). They were also
provided with a short explanation of the CBT-content
and therapy outline. Eighty-seven survivors completed
both the ‘need for help’ question and the CWS. The ma-
jority (74%) of the responders considered or expressed a
need for CBT (44% possibly; 30% yes). Almost the same
response pattern was seen in those with high FCR (35%
possibly; 30% yes) and those with low FCR (50% pos-
sibly; 30% yes) as based on the CWS. This procedure
was replicated amongst 86 colorectal cancer survivors.
Fifty-six percent of these survivors considered or
expressed a need for CBT (38% possibly; 18% yes). Colo-
rectal cancer survivors with high FCR were more open
to CBT compared to survivors with low FCR (Low FCR,
38% possibly; 10% yes: High FCR, 39% possibly, 32%
yes). Thus, a substantial number of cancer survivors in-
dicate a need for help with FCR.
● Content and structure of the intervention. The inter-
vention was developed by a collaboration of three clinical
psychologists (JP/HK/PS), two researchers (MG/MW) and
a psychiatrist (AS), all experienced in the field of psycho-
social oncology and working at the RUMC. After literature
consultation and multiple meetings, consensus was
reached on core components and key techniques of the
intervention (described in the section ‘Intervention: Cog-
nitive Behaviour Therapy for FCR’).
CBT is one of the best established interventions for
psychological problems in somatic conditions. In health
care settings, CBT is already frequently used for various
somatic problems such as fatigue and insomnia (Savard
et al. 2005; Gielissen et al. 2006). CBT is a structured,
action-oriented form of psychological treatment consist-
ing of techniques directed at identifying and modifying
negative (dysfunctional or unhelpful) thought patterns
and dysfunctional behaviours (Beck & Beck 2011). Since
cognitions, emotions and behaviours are interconnected, a
change in cognitions and/or behaviour initiates changes in
the other areas as well.
The intervention will be offered as blended therapy. In
blended therapy both online and offline therapy compo-
nents are integrated. A website is available that supports
the patient throughout the entire therapy as it runs paral-
lel to the face-to-face therapy sessions. The website has
been developed in collaboration with ICT specialists and
contains over 70 pages of content including information
(10 scripts), at-home assignments (27 tasks), assessments
(6 tests), audio (2 clips) and video (15 fragments). An in-
corporated library includes additional information on
cancer-related topics. A feature to engage in an electronic
consultation (‘e-consult’) with the assigned therapist is
supplementary to the face-to-face sessions. Because not all
survivors have access to the internet and some may lack
the required computer skills, a paper workbook (with
DVD/CD) will be available as well.
● Advisory Committee. The third step was to involve
health care workers and patient representatives as an ad-
visory committee in reviewing the therapy content. The
committee was composed of three cancer survivors
(breast, colorectal and prostate cancer) and three health
care workers (two nurse practitioners for breast cancer
and colorectal cancer care and a urologist). They were
asked to provide comments, ideas and suggestions to fur-
ther improve the intervention. In addition, a 13-item
close-ended questionnaire, answerable on a 5-point Likert
Scale (e.g. “Overall, what is your general impression of the
website?”) was completed and members were asked to
elaborate on their assigned score. The content and format
of the intervention were rated with a mean of 4.3 out 5
(a higher score indicating a more positive impression of
the intervention). With the generated feedback the con-
tent was slightly revised.
● Website usability testing. The user interface of the
prototype website was tested by three patient representa-
tives (breast, colorectal and prostate cancer) on feasibil-
ity and patient centeredness. A ‘think aloud procedure’
was employed, meaning that persons were asked to think
aloud while using the website in order to provide us with
more insight in 1) how the website is used without guid-
ance of a professional and 2) how encountered problems
are solved (Jaspers 2009). Afterwards the System Usabil-
ity Scale (SUS) (Brooke 1996; Bangora et al. 2008) and a
feedback form were completed. The SUS is a short
(10-item scale) which gives a global view of subjective
perception of usability, the mean total SUS score (range 0
- 100) given by the three survivors was 87, which indicates
a satisfactory level of perceived usability (Bangora et al.
2008).
● Pilot testing. Lastly, two therapists piloted the inter-
vention with two high fearful breast cancer survivors
who completed all therapy sessions. After some minor
revisions, the final content of the therapy manual was
established.
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Intervention: cognitive behaviour therapy for FCR
The intervention was developed as face-to-face CBT
with access to a website that provides online materials
and the option to engage in therapist-patient interaction.
For the therapists, a structured manual with a detailed
description of each therapy session has been developed.
The CBT covers 3 months and comprises five individual
one-hour face-to-face sessions (session 1, 2, 3, 5 and 8)
and three (15 minutes) e-consults or telephonic consul-
tations (session 4, 6 and 7). In order to sustain behaviour
change and monitor therapy progress, patients will be
invited for a booster session at 3-month follow-up.
Intervention components were partially based on
existing traditional CBT models for health anxiety and
generalised anxiety. As with other forms of CBT, the pri-
mary emphasis of the therapy is on perpetuating factors
of the problem in question. In this case, those factors
maintaining high FCR. The principal therapeutic tech-
niques are self-monitoring, cognitive restructuring (iden-
tification and re-attribution of unhelpful thoughts) and
exposure- and response prevention. Other techniques
are psychoeducation, relaxation, mindfulness, reframing,
modelling (patient videos), at-home assignments, goal
planning and attainment (Marks et al. 2011). The first
session is directed at case conceptualisation and formu-
lation of a personal FCR model, taking into account per-
sonal characteristics, triggers of fear, cognitions and
consequences of FCR (see Figure 1). The FCR model
guides the course of therapy by identifying the most ap-
propriate points or targets for intervention (e.g. unhelp-
ful cognitions). It is open to modification in the course
of therapy because new insights might require adjust-
ments in certain parts of the FCR model. The following
four sessions (session 2 to 5) focus on acceptance, on
identifying/modifying dysfunctional thinking patterns
and on behaviour modification. If desired by patient or
therapist, spouses will be invited to attend one or more
therapy sessions. The final three sessions (session 6 to
8) are directed at consolidation of therapy progress and
the establishment of a relapse prevention plan. Self-
management skills are reinforced and active contribu-
tion to therapy progress and goal setting is encouraged.
Completion of at-home assignments is of pivotal im-
portance in order to practice the skills learned during
therapy and to establish enduring change. A more de-
tailed description of the intervention by session is de-
scribed in Table 1.
Control condition: treatment as usual
Cancer survivors in the control condition have access to
TAU and will not be offered additional psychological
therapy for managing FCR. This condition reflects the
natural course of FCR over time and gives insight in the
standard care practices that are offered to persons
outside the study context (e.g. during routine medical
follow-up). In the period after cancer treatment all pa-
tients are offered medical follow-up appointments con-
form the recommendations of the Dutch guidelines in
oncology care (Comprehensive Cancer Centre the
Netherlands 2011). For colorectal cancer, the Dutch
guideline advises medical examinations every 6 months
during the first 2 years of follow-up, continued by yearly
examinations up to 5-years follow up. For breast cancer,
the Dutch guideline advises medical follow-up examina-
tions every 3 months during the first year, every 6 months
during the second year and examinations once a year dur-
ing 2 to 5 years follow-up. For prostate cancer, during the
first year after cancer treatment a follow-up schedule of
6 weeks, 3, 6, 9 and 12 months is recommended, and
semi-annually or annually thereafter for 5 to 10 years. In
the Netherlands, psychosocial follow-up is not institutio-
nalised and psychosocial care offered to cancer survivors
with high FCR therefore differs between health care insti-
tutions. Information on additional medical or psycho-
social care survivors have had during the study period
will be collected for both the interventions and the con-
trol group. This includes utilization of psychosocial ser-
vices (e.g. psychological therapy, mindfulness and social
work), health care consultations (e.g. GP, medical special-
ists, and paramedical assistance) or medication use.
Participating therapists
All CBT sessions will take place at the RUMC, department
of Medical Psychology in Nijmegen, the Netherlands.
The CBT will be practiced by two qualified, registered
healthcare psychologists with experience in delivering
CBT for somatic conditions and experience in the field
of psychosocial oncology. During the study, both thera-
pists will have regular supervision by a registered clin-
ical psychologist, also qualified as CBT supervisor (JP).
Before the start of the study, both therapists had
already performed one supervised treatment case con-
form the therapy manual.
Treatment integrity
To be able to draw valid conclusions on the therapy ef-
fects, treatment integrity (e.g. the implementation of the
treatment as intended) is ensured conform the guide-
lines established by the Behaviour Change Consortium
(Bellg et al. 2004), i.e. with the use of a standardised
therapy manual and ongoing therapist supervision. All
sessions will be audio taped and 5% will be randomly
checked for adequate therapy implementation.
Outcomes
Detailed information on the study outcomes is available
in Table 2. Participants will be asked to complete
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questionnaires at four different time points, either online
or on paper. Demographic and medical information will
be gathered with self-report questionnaires and from
medical records.
Screening and primary outcome
Participants will be screened on high Fear of cancer re-
currence with the Cancer Worry Scale (CWS). This
questionnaire is validated as a screening instrument and
is able to detect high FCR in Dutch cancer survivors
(Custers et al. 2014). A cut-off score of ≥ 14 appeared
optimal for differentiating high fearful patients from non-
fearful patients. The CWS has good psychometric proper-
ties (α = 0.87).
Secondary outcomes
Multidimensional aspects of FCR will be assessed with
the Fear of Cancer Recurrence Inventory (FCRI). The
Table 1 Content of the intervention by therapy session
Session Delivery Week Time (minutes) Session components
1 Face-to-face 1 90 • Case formulation: a patient’s story.
• Discuss therapy rationale.
• Establish therapy goals.
• Review FCR and complete a personal FCR model.
• Introduce at-home assignments.
2 Face-to-face 2 60 • Explain the basic tenets of CBT.
• Discuss and visualize the association between thoughts,
feelings and actions.
• Review the concept of helpful beliefs.
• Practice in filling out thought records.
• Introduce mindfulness and relaxation exercises.
3 Face-to-face 3 60 • Review the completed thought record(s) to identify unhelpful
thoughts and behavioural consequences of FCR.
• Differentiate realistic from unrealistic worries and establish
more helpful thoughts.
• Explore and identify dysfunctional behavioural patterns.
• Create a ranked list of situations that induce FCR and propose
a behavioural experiment.
• Practice a mindfulness or relaxation exercise.
4 E-consult (or telephone) 4 15 • Review of progress (troubleshooting).
• Encourage at-home skill practice.
5 Face-to-face 6 60 • Review therapy goals, discuss areas of concern and make
future plans (beyond therapy).
• Discuss completed thought records and/or behavioural
experiments.
• Identify personal strengths and resources of strength.
6 E-consult (or telephone) 7 15 • Review of progress (troubleshooting).
• Encourage at-home practice of skills.
7 E-consult (or telephone) 9 15 • Review of progress (troubleshooting).
• Introduce the relapse prevention plan.
8 Face-to-face 11 60 • Review therapy goals, progress made so far and discuss
possible future pitfalls.
• Define and finalize the relapse prevention plan.
• Evaluate the therapy process.
• Schedule an appointment for the booster session.
9 Face-to-face (booster session) 24 60 • Review the FCR model and progress made during therapy.
• Discuss difficult situations and how to overcome them.
• Relapse prevention plan.
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Table 2 Primary and secondary outcome measures of the SWORD-study
Primary outcome
Questionnaire Response format Example question Timepoints
Fear of cancer recurrence Cancer Worry Scale (CWS) (8 items) 4-point Likert scale *range 8 - 32 During the past month: “How often have you thought
about your chances of getting cancer (again)?”
Screening
T0;T1;T2;T3
Secondary outcomes
Dimensions of FCR Fear of Cancer Recurrence Inventory
(42-items)
5-point Likert scale “How many times per day do you spend thinking about the possible chance of
recurrence?” “I am worried or anxious about a possible chance of recurrence.” “I
try to replace this thought with a more pleasant one.”
T0;T1;T2;T3
Subscales:
• Triggers (8 items) −0 - 32
• Severity (9 items) −0 - 36
• Psychological distress (4 items) −0 - 16
• Functional impairment (6 items) −0 - 24
• Coping strategies (9-items) −0 - 36
• Insight (3 items) −0 - 12
• Reassurance Seeking (3 items) −0 - 12
Cancer related quality of life EORTC-QLC C30 (30 items) Subscales: 4-point Likert scale “Were you limited in pursuing your hobbies or other leisure time activities?”
“How would you rate your overall health during the past week? (Global health)”
T0;T1;T2;T3
• Five functional scales (15 items) −15 - 60
• Three symptom scales (7 items) −7 - 28
• Single symptom items (6 items) −6 - 24
• Global health & quality of life scales
(2 items)
−2 - 14
Cancer specific quality of life:
Breast cancer
EORTC-BR23 (23 items) Four
functional scales (8 items)
−8 - 32 “Have you felt physically less attractive as a result of your disease or
treatment?”
T0;T1;T2;T3
• Four symptom scales (15 items) −15 - 60
Cancer specific quality of life:
Prostate cancer
EORTC-PR25 (25 items) “Have you had difficulty going out of the house because you needed to be
close to a toilet?”
T0;T1;T2;T3
• Two functional scales (6 items) −6 - 24
• Four symptom scales (19 items) −19 - 76
Cancer specific quality of life:
Colorectal cancer
EORTC-CR38 (38 items) Two
functional scales (7 items)
−7 - 28 “During past week, where you bothered by gas (flatulence)?” T0;T1;T2;T3
• Seven symptom scales (28 items) −26 - 104
• Three single symptom items −1 - 4
Satisfaction with life Satisfaction With Life Scale (5-items) 7-point Likert scale *5 - 35 “In general, I am satisfied with life.” T0;T1;T2;T3
Distress Hospital Anxiety and Depression
Scale (14 items) Subscales
4-point Likert scale *0 - 42 “I feel tense or wound up” “I feel as if I am slowed down” T0;T1;T2;T3
• Anxiety (7 items) −0 - 21
• Depression (7 items) −0 - 21
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Table 2 Primary and secondary outcome measures of the SWORD-study (Continued)
Distress thermometer (1 item)
Problem List (47 items)
VAS *0 - 10 *0 - 47 “Circle the number (0-10) that best describes how much distress you have been
experiencing in the past week.”
T0;T1;T2;T3
Fatigue severity Checklist Individual Strength –
Fatigue Severity subscale (8 items)
7-point Likert scale *8 - 56 “I feel tired” “I am rested” T0;T1;T2;T3
Optimism Life orientation Test (LOT) (12 items) 5-point likert scale *0 - 32 “In uncertain times, I usually expect the best.” T0;T1;T2;T3
Body vigilance Body Vigilance Scale (4-items) VAS scale *0 - 10 item 1-3 *0 - 15
item 4
“I am very sensitive to changes in my internal
bodily sensations”
T0;T1;T2;T3
Coping with the experience
of cancer
Impact of Events Scale (15 items)
Subscales
4-point Likert scale *0 - 35 *0 - 40 “Any reminder brought back feelings about it.”
(intrusion)
T0;T1;T2;T3
• Intrusion (7 items)
• Avoidance (8 items)
Perceived social support Social Support List – Dissatisfaction
scale (34-item)
4-point likert scale *34 - 102 What is your opinion about the extent to which people…: “Drop in for a
pleasant visit?”
T0;T1;T2;T3
Personality Big Five Inventory (44 items)
Subscales Neuroticism (8 items)
5-point Likert scale I see myself as someone: “Who… can be somewhat careless.”
(conscientiousness) “Who… Is sometimes shy, inhibited.” (extraversion)
T0
• Extraversion (8 items)
• Openness (10 items)
• Conscientiousness (9 items)
• Agreeableness (9 items)
Health care use EQ-5D (5 items) EQ-5D thermometer 4-point Likert scale VAS Scale
(0 - 100)
“Please indicate which statement best describes your own health state today.” T0;T1;T2;T3
TIC-P – part I Open ended questions In the past 4 weeks did you “how often did you visit the general practitioner?” T0
Custom made cost diaries Open ended questions During the specified period: ‘How often did you consult the general practitioner
and why?’
Between T0-
T1 T1-T2 T2-
T3 T3-T4
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FCRI gives a global idea of FCR in the preceding month
and provides information about the principal character-
istics of FCR (e.g. fear invoking stimuli/situations). The
FCRI consists of 7 subscales; Triggers, Severity, Psycho-
logical distress, Coping strategies, Functioning Impair-
ments, Insight, and Reassurance (Simard & Savard 2009).
Quality of Life will be measured with the Dutch version
of the European Organization for Research and Treatment
of Cancer (EORTC) Quality of Life Questionnaire Core 30
(QLQ-C30). Complementary to the QLQ-C30, disease
specific modules for breast cancer (QLQ-BR23), colorectal
cancer (QLQ-CR38) and prostate cancer (QLQ-PR25) will
be assessed (Aaronson et al. 1993). Both the EORTC-
QLQ-C30 and the disease specific modules have demon-
strated moderate to good psychometric properties and
clinical validity in cancer survivors (Aaronson et al. 1993;
Sprangers et al. 1996; Sprangers et al. 1999; van Andel
et al. 2008).
Satisfaction with life will be evaluated with the Satis-
faction With Life Scale (SWLS). The SWLS has suffi-
cient psychometric properties (α = .87) and is able to
detect changes in life satisfaction over time (Diener et al.
1985).
Distress will be measured with the Hospital Anxiety
and Depression Scale (HADS) total score (Annunziata
et al. 2011; Vodermaier & Millman 2011). In addition,
the Dutch version of the Distress Thermometer (DT)
and the problem list will be completed as well (Tuinman
et al. 2008).
Fatigue severity will be assessed with the fatigue sever-
ity subscale of the Checklist Individual Strength (CIS-
8R) (Dittner et al. 2004; Servaes et al. 2002).
Bodily vigilance refers to the tendency to focus on in-
ternal bodily sensations and will be assessed with the
four-item Body Vigilance Scale (Schmidt et al. 1997).
Coping with the experience of cancer will be measured
with the Impact of Events Scale. This scale consists of
15 items that ask for the frequency of cancer-related avoi-
dant and intrusive cognitions or behaviours (Horowitz
et al. 1979) .
Perceived social support, or rather the perceived dis-
crepancy between a patient’s desired social support and
the actual amount of social support received, will be
assessed with the Social Support List – Dissatisfaction
(SSL-D) scale (Van Sonderen & Ormel 1997).
Personality dimensions will be measured with the Big
Five Inventory (BFI) (Denissen et al. 2008). This is a 44-
item multidimensional personality inventory that covers
the five main dimensions of personality trait (conscien-
tiousness, agreeableness, emotional stability, extroversion
and intellect or openness (John & Srivastava 1999)).The
BFI will only be administered at baseline (T0).
Optimism, as a dispositional trait, will be assessed with
the Life Orientation Test (LOT). This questionnaire
contains twelve items on the optimistic and pessimistic
trait of personality (Scheier & Carver 1985).
Health Care Use/cost-effectiveness: The EuroQol-5D
(EQ-5D) will be used to calculate cost-utility. It has
shown to be an appropriate measure for economic evalua-
tions in health interventions with breast cancer patients
after treatment (Kimman et al. 2009). The instrument is
able to detect changes in patients’ self-reported health
related quality of life and has good psychometric prop-
erties (Kimman et al. 2009; Ravens-Sieberer 2010).
Health care costs will be further monitored with cost
diaries and the Trimbos/iMTA Costs associated with
Psychiatric Illness (TiC-P) questionnaire (Hakkaart-Van
Roijen 2002). Patients will be asked to report both dir-
ect health care costs (e.g. use of health care services,
change of prescribed medication) and indirect costs
(e.g. absence from work) during specified time periods
(see Table 2).
Technical usage statistics (intervention condition only)
Website use and completion of exercises can be seen as
a form of treatment adherence. This includes data on
number of exercises completed, frequency of logins, time
online and webpages opened (Donkin et al. 2011). Tech-
nical data for those using the workbook will include the
number of exercises completed.
Intended statistical analyses
SPSS will be used for all statistical analyses. All statistical
tests will be two-sided (level of significance = 0.05). To
ensure that the key variables are evenly distributed by
randomisation, baseline characteristics will be compared
between the two conditions with Chi-square (categorical
variables) and ANOVA (continuous variables) testing.
Primary efficacy analysis will be conducted in agreement
with the intention-to-treat principle. Additionally, a per-
protocol analysis will be conducted using the data for
those who successfully completed the intervention. Dif-
ferences between the two conditions in the amount of
change in FCR (T0 and T1) will be calculated with
ANCOVA-analysis. Later, the follow-up effects (T3, T4)
will be investigated with longitudinal data analysis. Next
to statistical significance the clinically significant im-
provement will be established according to the method
by Jacobson & Truax, calculating the reliable change
index (Jacobsen & Truax 1984).
Discussion
While cancer survivors report FCR to be a key concern
and unmet need no clear consensus exists on the best
management strategies for FCR in clinical practice. The
SWORD-study protocol describes a trial that will
evaluate blended CBT as intervention for high FCR in
cancer survivors. The primary aim is to reduce high
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FCR to more acceptable and less debilitating levels. Both
post-intervention and follow-up effects of the therapy will
be assessed. If efficacy can be demonstrated, an evidence-
based therapy for high FCR will become available.
Strengths of this study include: an intervention specif-
ically targeted at high FCR, the inclusion of breast, colo-
rectal and prostate cancer survivors, screening for high
FCR and the inclusion of survivors up to five years post
medical treatment. Until now, only one published (feasi-
bility) trial investigated an intervention specifically tar-
geted at high FCR. Other studies have mentioned FCR
as a secondary outcome or have investigated related
constructs (e.g. FoP). Furthermore, because interven-
tions were mostly targeted at survivors of breast or gy-
naecological cancer there was an overrepresentation of
women in all samples (88-100% women). It is assumed
that men and women experience and deal with emo-
tional problems differently. Women are more comfort-
able in disclosing their feelings than men and might be
more inclined to seek and accept expert help (Northouse
et al. 2000). It is therefore debatable whether comparable
intervention effects can be achieved in male cancer sur-
vivors. In order to overcome this problem, our trial in-
cludes survivors of male (prostate), female (breast) and
mixed gender (colorectal) cancer.
FCR is a concern for many cancer survivors, ranging
from mild to high levels. Hence, different forms of care,
each with different intensity, should be available to can-
cer survivors based on their individual needs (Bower &
Gilbody 2005). The first level of tailored care for milder
FCR may only comprise of patient education or psycho-
education while survivors with moderate FCR could
benefit from a more intensive approach such as empow-
ering self-management through internet therapy. High
specialised care can comprise individual CBT, of which
our intervention would be a good example. In order to
identify those who might benefit most from blended
CBT screening for high FCR will take place and those
scoring above the specified threshold (CWS ≥14) will be
asked to participate.
To conclude, the current trial will answer the question
whether blended CBT is an effective intervention to man-
age high FCR in breast, prostate and colorectal cancer sur-
vivors. If so, an evidence-based therapy to manage high
FCR will become available for use in clinical practice.
Additional file
Additional file 1: Appendix A. Interventions specifically targeted at FCR
(or FoP). Appendix B. Interventions that mention FCR as secondary outcome.
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